DKTK-Studienregister

DetailsucheDetailsuche
Klicken Sie auf Detailsuche, um z.B. nach Therapielinie, molekularem Marker oder Rekrutierungsstatus zu suchen.
FreitextsucheFreitextsuche
Sie können hier nach dem Studienkurzcode oder einem Teil des Studientitels suchen.
Studienauswahl
Zentren
Status der Studie

» Hämatologische Neoplasien » NHL

Alle Linien

AMG 562 20170533
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma (Aktiv)

B-NHL 2013
B-NHL 2013 - Behandlungsprotokoll der NHL-BFM und der NOPHO-Studiengruppen für reife aggressive B-Zell-Lymphome und -Leukämien bei Kindern und Jugendlichen (Aktiv)

CZAR-1
fficacy and safety of Carfilzomib in combination with Ibrutinib for patients with Waldenström's macroglobulinemia (CZAR-1) (Aktiv)

GO29781
A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (Aktiv)

JCAR017-BCM-004
JE A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) (Aktiv)

POLE-1
Efficacy of pembrolizumab in patients with marginal zone lymphoma (Aktiv)

Pix in DLBCL first line
R-CPOP as first line therapy (Aktiv)

Erstlinie

ImbruVeRCHOP
Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL (Aktiv)

NHL 3-2004
Therapy Optimisation for the Treatment of Hairy Cell Leukemia (Aktiv)

OLYMP-1
Obinutuzumab in Marginal Zone Lymphoma (Aktiv)

Zweitlinie oder später

67856633LYM1001
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (Aktiv)

CHARLY
Study on the value of post-transplant Cyclophosphamide after Thiotepa-based haplo-identical stem-cell transplantation for relapsed-refractory lymphoma (Aktiv)

CNIR178X2201
Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)

CVOB560A12101
A Phase Ib, Multicenter Study of VOB560 in Combination With MIK665 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma. (Aktiv)

GC-LTFU-001
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (Aktiv)

GOAL
Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) incombination with PixantrOne (Aktiv)

Lymrit-37-01
A Phase I/II Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma. (Aktiv)

M13-833
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies (Aktiv)

MB-CART19.1 r/r CD19+ BCM
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) (Aktiv)

NP40126
A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas (Aktiv)

Pix in DLBCL first line
R-CPOP as first line therapy (Aktiv)

R1979-ONC-1625
Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (Aktiv)

REGN1979-HM-1333
This is an open-label, multi-center, dose escalation study of REGN1979 administered as an IV (intravenous) infusion. This phase 1 study will investigate the safety and tolerability of REGN1979 in patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (Aktiv)

DKTK-Studienregister
Dr. N. Gökbuget, Dipl.-Biol. K. Ihrig | Ohne Gewähr für Richtigkeit oder Vollständigkeit | ccp@dkfz.de